
Phillip D Fromm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/979630/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinguishing human peripheral blood CD16 + myeloid cells based on phenotypic characteristics. Journal of Leukocyte Biology, 2020, 107, 323-339.	1.5	8
2	Examination of CD302 as a potential therapeutic target for acute myeloid leukemia. PLoS ONE, 2019, 14, e0216368.	1.1	13
3	Dendritic cells as cancer therapeutics. Seminars in Cell and Developmental Biology, 2019, 86, 77-88.	2.3	50
4	A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. Oncolmmunology, 2018, 7, e1419114.	2.1	24
5	CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica, 2018, 103, 655-665.	1.7	24
6	The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population. Journal of Immunology, 2016, 197, 4613-4625.	0.4	34
7	CMRF-56 ⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Oncolmmunology, 2016, 5, e1168555.	2.1	17
8	Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration. Journal of Immunology, 2016, 197, 885-898.	0.4	28
9	A CD2 highâ€expressing stressâ€resistant human plasmacytoid dendriticâ€cell subset. Immunology and Cell Biology, 2016, 94, 447-457.	1.0	34
10	CD16+ Dendritic Cells Are a Unique Myeloid Antigen Presenting Cell Population. Blood, 2016, 128, 4897-4897.	0.6	6
11	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacological Reviews, 2015, 67, 731-753	7.1	129